Brady W. Dougan

Brady W. Dougan is a declared insider of Humacyte, Inc. (board member), with filings sourced from SEC (Form 4). Over a trading history stretching from 26 August 2021 to 20 August 2025, the count stands at 46 filings.

Both buying and selling appear: 8 purchases worth €13.1M, against 34 sales worth €70.1M. Taken together, the sales exceed the purchases by €57.0M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 2 share grants and 2 option exercises. So far in 2025, the count stands at no purchases and 3 sales.

In size, the median ticket on the buying side is €14k. On 7 out of 7 purchases, another insider of the same company was buying within the same 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. For 7 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 14% of cases, with a median move of -17.0%. These figures describe past trades and do not predict future prices.

The latest filing, published on 20 August 2025, reports an open-market sale of €1.5M in Humacyte, Inc. The latest purchase dates back some time: it was published 702 days ago, on 21 November 2024. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.